Movement Alert｜WUXI XDC Rises 3.81% in Regular Trading, Sector-Wide Rebound and Strong Interim Results Provide Dual Support

On September 14, WUXI XDC rose 3.81% in regular trading, trading at HK$74.85/share, with turnover of HK$142 million. The stock rebounded as selling pressure from a major parent-company stake reduction eased, while a broad-based rally across the Life Sciences Tools & Services sector and robust interim earnings provided support.

On the sector front, peers rallied in tandem, with Pharmaron up 5.45%, GenScript Biotech up 5.13%, WuXi Biologics up 4.64%, WuXi AppTec up 4.08%, and InSilico up 2.28%, reflecting strong sector-wide momentum. The rebound follows several sessions of weakness triggered by WuXi AppTec and affiliates offloading approximately 53.52 million WUXI XDC shares via block trades at an average price of HK$73.23, reducing their stake from 18.36% to 14.14% and involving proceeds of approximately HK$3.92 billion.

Fundamentally, WUXI XDC reported strong H1 results on August 24, with revenue of RMB 3.701 billion, up 37.0% year-over-year, adjusted net profit of RMB 1.027 billion, up 37.4%, and gross margin improving to 37.0%. Notably, the company's unfilled order backlog reached US$2.2 billion, surging 62.2% year-over-year, underscoring robust demand visibility for its global ADC/XDC CRDMO services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)